Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1986 Apr;49(4):390–395. doi: 10.1136/jnnp.49.4.390

Mesulergine in early Parkinson's disease: a double blind controlled trial.

E Dupont, B Mikkelsen, J Jakobsen
PMCID: PMC1028763  PMID: 3517235

Abstract

The efficacy and tolerance of treatment with an 8-alpha-amino-ergoline derivative CU32-o85, Mesulergine, were compared with levodopa/benserazide (Madopar) in a 3 month double-blind controlled trial in 31 patients with Parkinson's disease, not previously treated with levodopa. The two treatments were equally well tolerated, and neither dyskinesias nor dose-related fluctuations developed. In 90% of the patients treated with Mesulergine, Parkinsonian symptoms improved, and at the dose given the overall therapeutical response was two-thirds that of levodopa. During further 9 months of open study the beneficial effect was maintained equally well in both groups. Compared with other dopamine agonists Mesulergine has a considerable antiparkinsonian effect. Unfortunately, further clinical evaluation of the compound recently has been stopped owing to sex and species specific histological alterations in rats. It is suggested that Mesulergine derivatives might well be of value in future treatment of early Parkinson's disease and of late incompensated stages.

Full text

PDF
390

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biesemeyer H., Ludin H. P., Ringwald E. Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease. J Neurol. 1983;230(1):19–23. doi: 10.1007/BF00313593. [DOI] [PubMed] [Google Scholar]
  2. Calne D. B., Plotkin C., Williams A. C., Nutt J. G., Neophytides A., Teychenne P. F. Long-term treatment of parkinsonism with bromocriptine. Lancet. 1978 Apr 8;1(8067):735–738. doi: 10.1016/s0140-6736(78)90856-5. [DOI] [PubMed] [Google Scholar]
  3. Enz A. Biphasic influence of a 8 alpha-amino ergoline, CU 32-085, on striatal dopamine synthesis and turnover in vivo in the rat. Life Sci. 1981 Nov 23;29(21):2227–2234. doi: 10.1016/0024-3205(81)90494-x. [DOI] [PubMed] [Google Scholar]
  4. Fahn S., Cote L. J., Snider S. R., Barrett R. E., Isgreen W. P. The role of bromocriptine in the treatment of parkinsonism. Neurology. 1979 Aug;29(8):1077–1083. doi: 10.1212/wnl.29.8.1077. [DOI] [PubMed] [Google Scholar]
  5. Flückiger E., Briner U., Bürki H. R., Marbach P., Wagner H. R., Doepfner W. Two novel prolactin release-inhibiting 8 alpha-amino-ergolines. Experientia. 1979 Dec 15;35(12):1677–1678. doi: 10.1007/BF01953267. [DOI] [PubMed] [Google Scholar]
  6. Graham D. G., Tiffany S. M., Bell W. R., Jr, Gutknecht W. F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol. 1978 Jul;14(4):644–653. [PubMed] [Google Scholar]
  7. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  8. Lesser R. P., Fahn S., Snider S. R., Cote L. J., Isgreen W. P., Barrett R. E. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 1979 Sep;29(9 Pt 1):1253–1260. doi: 10.1212/wnl.29.9_part_1.1253. [DOI] [PubMed] [Google Scholar]
  9. Lieberman A. N., Kupersmith M., Gopinathan G., Estey E., Goodgold A., Goldstein M. Bromocriptine in Parkinson disease: further studies. Neurology. 1979 Mar;29(3):363–369. doi: 10.1212/wnl.29.3.363. [DOI] [PubMed] [Google Scholar]
  10. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  11. Pakkenberg H., Jensen I. Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085. Adv Neurol. 1983;37:151–157. [PubMed] [Google Scholar]
  12. Parkes J. D., Debono A. G., Marsden C. D. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry. 1976 Nov;39(11):1101–1108. doi: 10.1136/jnnp.39.11.1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Quinn N. P. Anti-parkinsonian drugs today. Drugs. 1984 Sep;28(3):236–262. doi: 10.2165/00003495-198428030-00002. [DOI] [PubMed] [Google Scholar]
  14. Rascol A., Montastruc J. L., Guiraud-Chaumeil B., Clanet M. La bromocriptine comme premier traitement de la maladie de Parkinson. Résultats à long terme. Rev Neurol (Paris) 1982;138(5):401–408. [PubMed] [Google Scholar]
  15. Ringwald E., Hirt D., Markstein R., Vigouret J. M. Dopaminrezeptoren-Stimulatoren in der Behandlung der Parkinsonkrankheit. Nervenarzt. 1982 Feb;53(2):67–71. [PubMed] [Google Scholar]
  16. Schneider E., Hubener K., Fischer P. A. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085. Neurology. 1983 Apr;33(4):468–472. doi: 10.1212/wnl.33.4.468. [DOI] [PubMed] [Google Scholar]
  17. Teychenne P. F., Bergsrud D., Racy A., Elton R. L., Vern B. Bromocriptine: low-dose therapy in Parkinson disease. Neurology. 1982 Jun;32(6):577–583. doi: 10.1212/wnl.32.6.577. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES